SCHEMBL3422130

SCHEMBL3422130

COc1cc2c(Oc3ccc(N(C(=O)C4(C(N)=O)CC4)c4ccccc4)cc3F)ccnc2cc1OCCCC1(O)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 19/20 0.52
AXL P30530 3/20 0.48
KDR P35968 3/20 0.48
HDAC2 Q92769 2/20 0.48
HDAC8 Q9BY41 2/20 0.48
HDAC6 Q9UBN7 2/20 0.48
RET P07949 2/20 0.48
PDGFRB P09619 2/20 0.48
KIT P10721 2/20 0.48
FLT3 P36888 2/20 0.48
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
PLK4 O00444 1/20 0.46
STK25 O00506 1/20 0.46
CIT O14578 1/20 0.46
AURKA O14965 1/20 0.46
CHUK O15111 1/20 0.46
MUSK O15146 1/20 0.46
EPHB6 O15197 1/20 0.46
MAPK13 O15264 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2158756 0.95 MET (0.54) METAXLKDRHDAC2HDAC8
SCHEMBL2158304 0.88 AXL (0.39) METAXLKDRIGF1RMERTK
SCHEMBL3233656 0.87 AXL (0.55) METAXLKDRHDAC2HDAC8
Hydrochloric Acid SCHEMBL15918148 0.87 MET (0.56) METAXLKDRHDAC2HDAC8
SCHEMBL3675221 0.87 MET (0.55) METAXLKDRHDAC2HDAC8
Hydrochloric Acid SCHEMBL15917934 0.87 MET (0.56) METAXLKDRHDAC2HDAC8
Hydrochloric Acid SCHEMBL15917992 0.87 MET (0.56) METAXLKDRHDAC2HDAC8
SCHEMBL28676846 0.87 MET (0.57) METAXLKDRHDAC2HDAC8
SCHEMBL28692805 0.86 HDAC2 (0.56) METAXLKDRHDAC2HDAC8
SCHEMBL30786374 0.86 HDAC2 (0.56) METAXLKDRHDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2532657-B9 Compounds and methods of use SUNSHINE LAKE PHARMA CO LTD (CN) 2017-04-19 EP disclosed
EP-2532657-B1 Compounds and methods of use SUNSHINE LAKE PHARMA CO LTD (CN) 2016-08-31 EP disclosed
US-8426585-B2 Compounds comprising a spiro-ring Xi, Ning (US) 2013-04-23 US disclosed
US-20120315247-A1 COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2012-12-13 US disclosed
EP-2532657-A2 Compounds and methods of use Sunshine Lake Pharma Co., Ltd (CN) 2012-12-12 EP disclosed
US-8293897-B2 Compounds comprising a spiro-ring and methods of use Xi, Ning (US) 2012-10-23 US disclosed
WO-2010045095-A1 COMPOUNDS AND METHODS OF USE XI NING (US) 2010-04-22 WO disclosed
US-20100093727-A1 COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093727-A1 COMPOUNDS AND METHODS OF USE PRKDC, PRKACA, PRKX MET 302/4885AXL 719/4885KDR 600/4885
US-20120315247-A1 COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE CDC42BPG, HRAS, PTPRJ MET 732/4885AXL 1146/4885KDR 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.